- About Us
- Guidelines
-
The Author ensures that the research has been conducted responsibly and ethically with adherence to all relevant regulations. read more..
- For Authors
- For Reviewer
- Manuscript Guidelines
- Membership
- Publication Ethics
-
- Journals
- Reprints
- e-Books
- Videos
- Indexing
- Contact Us
COVID-19
- Submissions
Abstract
Gastroenterology Medicine & Research
Safety of Everolimus in Living Donor Liver Transplantation Recipients with Severe Renal Dysfunction with Low Estimated Glomerular Filtration Rate: Can Everolimus Help in Renal Recovery?
-
Open or Close Ashok Thorat*
Medical University Hospital, China
*Corresponding author: Ashok Thorat, Medical University Hospital, Yuh-Der Road, North District, Taichung, China
Submission: September 10, 2017; Published: December 15, 2017
ISSN 2637-7632Volume1 Issue1
Abstract
Chronic renal dysfunction is a frequent and severe complication in solid-organ transplant recipients. Switching from calcineurin inhibitors (CNIs) to non-nephrotoxic mammalian target of rapamycine inhibitors (mTORi) such as everolimus (EVR) can improve renal function in these patients. Single center prospective study by Castroagudín et al. [1] has shown an improvement of renal function after addition of the EVR to primary immunosuppression and reducing the CNIs [1].
Editor In Chief
.jpg)
Signup for Newsletter
Quick Links
Editorial Board Registrations
Submit your Article
Best Paper of the Volume
Reprints
Refer a Friend
Advertise With UsOur Recent Edition
.jpg)
Top Editors
.jpg)
.bmp)
.jpg)
.png)
.jpg)
.png)
.png)
.png)
Financial Support
Sponsors
Latest e-Books
Latest Video
a Creative Commons Attribution 4.0 International License. Based on a work at www.crimsonpublishers.com.
Best viewed in 
| Above IE 9.0 version